Healthcare >> CEO Interviews >> July 1, 1998
STANLEY T. CROOKE is Founder, Chairman and Chief Executive Officer of
Isis Pharmaceuticals, Inc. Dr. Crooke is currently a member of the Board
of Directors of Applied Molecular Evolutions, Inc., San Diego,
California, EPIX Medical, Inc., Cambridge, Massachusetts; Idun
Pharmaceuticals, Inc., La Jolla, California; Valentis, Inc., Burlingame,
California; SYNSORB Biotech, Inc., Calgary, Alberta, Canada; and Axon
Instruments, Inc., Foster City, California. He is a member of the IBC
Advisory Council, Current Drugs Advisory Board, the Editorial Advisory
Board of Journal of Drug Targeting and Antisense Research and
Development, the Editorial Board of Gene Therapy and Molecular Biology.
He is also Editor-in-Chief of Current Opinion in Anticancer Drugs and
Section Editor for Biologicals and Immunologicals for Expert Opinion on
Investigational Drugs. He has been appointed by the American Association
for Cancer Research to serve as a member of the California State
Legislative Committee. Prior to founding Isis, Dr. Crooke was President
of Research and Development for SmithKline Beckman Corporation. He also
coordinated the research and development activities of SKB including its
instruments, diagnostics, animal health and clinical laboratory
businesses. Prior to joining SKB, Dr. Crooke helped establish the
anticancer drug discovery and development program at Bristol-Myers,
which succeeded in bringing to market a significant number of drugs. In
addition to his involvement in the pharmaceutical industry, Dr. Crooke
also maintains active academic positions. He is an Adjunct Professor at
University of California, San Diego and San Diego State University, and
has won a number of teaching awards. He has authored over 415
publications and has edited 19 books. Dr. Crooke is active in molecular
and cellular biology and pharmacology of antisense oligonucleotides. Profile
bring us up to date. What do you see over the next two to three years as
the key challenges and opportunities for ISIS?
